The treatment of RAS with PTRA may be difficult because of arterial wall thinning, friability, and the firm elastic recoil of the intramural lesion in some conditions such as NF-1, William syndrome, or mid-aortic syndrome. The gene discussed is NF1; the disease is atypical coarctation of aorta.